NZ603040A - Compound for treatment of respiratory condition or disease - Google Patents

Compound for treatment of respiratory condition or disease

Info

Publication number
NZ603040A
NZ603040A NZ60304011A NZ60304011A NZ603040A NZ 603040 A NZ603040 A NZ 603040A NZ 60304011 A NZ60304011 A NZ 60304011A NZ 60304011 A NZ60304011 A NZ 60304011A NZ 603040 A NZ603040 A NZ 603040A
Authority
NZ
New Zealand
Prior art keywords
treatment
disease
compound
respiratory condition
ethoxy
Prior art date
Application number
NZ60304011A
Other languages
English (en)
Inventor
John Nicholas Lambert
Janet Marie Wilson
Jane Ryan
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of NZ603040A publication Critical patent/NZ603040A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ60304011A 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease NZ603040A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (1)

Publication Number Publication Date
NZ603040A true NZ603040A (en) 2015-03-27

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60304011A NZ603040A (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Country Status (16)

Country Link
US (1) US20110257192A1 (OSRAM)
EP (1) EP2558097B1 (OSRAM)
JP (1) JP6148618B2 (OSRAM)
KR (1) KR20130106267A (OSRAM)
CN (2) CN102844032A (OSRAM)
AU (1) AU2011241478B2 (OSRAM)
BR (1) BR112012026244A2 (OSRAM)
CA (1) CA2796207A1 (OSRAM)
EA (1) EA025224B1 (OSRAM)
ES (1) ES2647223T3 (OSRAM)
IL (1) IL222244A0 (OSRAM)
MX (1) MX2012011938A (OSRAM)
NZ (1) NZ603040A (OSRAM)
SG (2) SG184430A1 (OSRAM)
WO (1) WO2011127538A1 (OSRAM)
ZA (1) ZA201207696B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229140B (zh) 2013-04-12 2022-06-10 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
US9802926B2 (en) 2014-06-20 2017-10-31 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
DE602004014728D1 (de) * 2003-02-21 2008-08-14 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
WO2006029182A2 (en) * 2004-09-07 2006-03-16 The La Jolla Institute For Molecular Medicine Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2725618C (en) * 2008-05-27 2016-04-12 Biota Scientific Management Pty Ltd Antiviral salts
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
MX2012011938A (es) 2013-01-28
ZA201207696B (en) 2014-03-26
EA201201416A1 (ru) 2013-03-29
US20110257192A1 (en) 2011-10-20
WO2011127538A1 (en) 2011-10-20
AU2011241478A1 (en) 2012-11-01
AU2011241478B2 (en) 2016-12-01
SG184430A1 (en) 2012-11-29
EP2558097A4 (en) 2013-09-11
ES2647223T3 (es) 2017-12-20
IL222244A0 (en) 2012-12-31
JP6148618B2 (ja) 2017-06-14
EP2558097A1 (en) 2013-02-20
CN105560245A (zh) 2016-05-11
KR20130106267A (ko) 2013-09-27
JP2013523844A (ja) 2013-06-17
SG10201502391WA (en) 2015-05-28
BR112012026244A2 (pt) 2016-07-12
CA2796207A1 (en) 2011-10-20
EA025224B1 (ru) 2016-12-30
EP2558097B1 (en) 2017-10-25
CN102844032A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
WO2009008001A3 (en) Inhalation device
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
DE112010004298A5 (de) Vorrichtung zum absaugen des sputums bei tracheotomie-patienten sowie innenkanüle für eine trachealkanüle
TWI561260B (en) Dose unit, pack of dose units and inhaler for inhalation of combination of drugs
NZ606977A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
MX394276B (es) Inhalador de polvo seco y metodo de uso
NZ603040A (en) Compound for treatment of respiratory condition or disease
TR201002877A2 (tr) Blister ambalaj içeren inhalasyon cihazı
EP2442657A4 (en) USE OF R-BAMBUTEROL AS INHALED MEDICAMENT AND COMBINATION THERAPIES FOR THE TREATMENT OF RESPIRATORY DISEASES
NO20082439L (no) Anvendelse av tiotropiumsalter for behandling av moderat vedvarende astma
MX2010003618A (es) Lisina de aztreonam inhalada para el tratamiento de deficits en la calidad de vida relacionada con la salud en enfermedades pulmonares.
ATE504301T1 (de) Verwendung von natriumblockern zur frühzeitigen behandlung von obstruktiven lungenerkrankungen
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
TR200909788A2 (tr) Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
IL213770A (en) Use of Fibert to prepare a drug to treat sleep apnea
EA201190087A1 (ru) Димерный пирролопиримидиндион и его применение в терапии респираторных заболеваний
WO2009137611A9 (en) Treatment of pulmonary fungal infection with voriconazole via inhalation
CN201848032U (zh) 一种口罩
CN203123241U (zh) 一种新型综合内科鼻氧塞
CN202568994U (zh) 组合型吸引装置
CN201692499U (zh) 吸痰保护罩
CN202315016U (zh) 一种肺结核病用杀菌消毒装置
UA37658U (en) Device for thoracocentesis
Reynolds Drug development for emerging infections

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 APR 2018 BY DAVIES COLLISON CAVE

Effective date: 20150630

LAPS Patent lapsed